

# Sychev Dmitry

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4548256/publications.pdf>

Version: 2024-02-01

188  
papers

671  
citations

759190

12  
h-index

940516

16  
g-index

209  
all docs

209  
docs citations

209  
times ranked

597  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 413-420.                       | 2.2 | 25        |
| 2  | Influence of <i>ABCB1</i> and <i>CYP3A5</i> gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 43-49.                     | 0.7 | 24        |
| 3  | The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. Pharmacogenomics and Personalized Medicine, 2016, Volume 9, 89-95. | 0.7 | 18        |
| 4  | Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. Drug Metabolism and Personalized Therapy, 2017, 32, 129-136.                              | 0.6 | 17        |
| 5  | Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. Human Psychopharmacology, 2018, 33, e2677.                     | 1.5 | 17        |
| 6  | Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. Canadian Journal of Physiology and Pharmacology, 2019, 97, 781-785.                             | 1.4 | 16        |
| 7  | CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genetic Testing and Molecular Biomarkers, 2018, 22, 51-54.   | 0.7 | 15        |
| 8  | Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genetic Testing and Molecular Biomarkers, 2017, 21, 747-753.   | 0.7 | 14        |
| 9  | <i>CYP2C19</i> polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 107-114.  | 0.7 | 14        |
| 10 | Effects of <i>ABCB1</i> rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I&ndash;II hypertension. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 157-165.              | 0.7 | 14        |
| 11 | Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and Personalized Medicine, 2018, Volume 11, 113-119.               | 0.7 | 14        |
| 12 | Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population. Rational Pharmacotherapy in Cardiology, 2019, 15, 393-406.   | 0.8 | 14        |
| 13 | Decision support systems in clinical practice: The case of venous thromboembolism prevention. International Journal of Risk and Safety in Medicine, 2015, 27, S104-S105.  | 0.6 | 13        |
| 14 | ADME pharmacogenetics: future outlook for Russia. Pharmacogenomics, 2019, 20, 847-865.  | 1.3 | 12        |
| 15 | Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. Gene, 2020, 739, 144513.                                 | 2.2 | 12        |
| 16 | The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmacogenomics and Personalized Medicine, 2015, 8, 111.  | 0.7 | 11        |
| 17 | Comparison of <i>CYP2C9</i> , <i>CYP2C19</i> , <i>CYP2D6</i> , <i>ABCB1</i> , and <i>SLCO1B1</i> gene-polymorphism frequency in Russian and Nanai populations. Pharmacogenomics and Personalized Medicine, 2017, Volume10, 93-99.             | 0.7 | 11        |
| 18 | EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2015, 11, 85-91.   | 0.8 | 11        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Clinical pharmacology in Russia—historical development and current state. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 159-163.  | 1.9 | 10        |
| 20 | Which cytochrome P450 metabolizes phenazepam? Step by step <i>in silico</i> , <i>in vitro</i> , and <i>in vivo</i> studies. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 65-73.   | 0.6 | 10        |
| 21 | Pharmacogenetics of alcohol addiction: current perspectives. <i>The Application of Clinical Genetics</i> , 2019, Volume 12, 131-140.   | 3.0 | 10        |
| 22 | CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 29-37.                             | 0.7 | 10        |
| 23 | How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .  | 0.6 | 9         |
| 24 | Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 209-215.  | 0.7 | 8         |
| 25 | The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 1-5.   | 0.7 | 8         |
| 26 | Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. <i>Molecular Biology Reports</i> , 2019, 46, 2761-2769.   | 2.3 | 8         |
| 27 | A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 205-212.  | 0.6 | 7         |
| 28 | Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 253-259.   | 0.7 | 7         |
| 29 | Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking $\beta$ -blockers in the Republic of Sakha (YAKUTIA). <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 195-200. | 0.6 | 7         |
| 30 | The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 109-118.  | 0.6 | 7         |
| 31 | Potential of the Transdermal Drug Delivery Systems for the Topical Treatment of Chronic Venous Diseases. <i>Flebologiya</i> , 2018, 12, 40.  | 1.0 | 7         |
| 32 | CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. <i>Pharmacogenomics and Personalized Medicine</i> , 2018, Volume 11, 107-112.   | 0.7 | 6         |
| 33 | Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 91-98.                                | 0.6 | 6         |
| 34 | Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. <i>Pharmacogenomics</i> , 2020, 21, 677-694.  | 1.3 | 6         |
| 35 | Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .  | 0.6 | 6         |
| 36 | A case of hepatic injury suspected to be caused by Canephron N, a Centaurium Hill containing phytotherapeutics. <i>International Journal of Risk and Safety in Medicine</i> , 2011, 23, 5-6.   | 0.6 | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 173-178.  | 0.6 | 5         |
| 38 | Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. <i>Drug Metabolism and Personalized Therapy</i> , 2018, 33, 187-194.                        | 0.6 | 5         |
| 39 | Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. <i>Drug Metabolism and Personalized Therapy</i> , 2019, 34, .   | 0.6 | 5         |
| 40 | Drugâ€“drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2020, .  | 0.6 | 5         |
| 41 | The effect of anticholinergic medications on cognitive function of patients 80 years and older with essential hypertension. <i>Arterial Hypertension (Russian Federation)</i> , 2019, 25, 246-257.   | 0.4 | 5         |
| 42 | APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 698-700.   | 0.8 | 4         |
| 43 | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 416-421.   | 0.8 | 4         |
| 44 | Do <em>CYP2C19</em> and<em> ABCB1</em> gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume 10, 243-245.       | 0.7 | 4         |
| 45 | Physicianâ€™s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. <i>Rational Pharmacotherapy in Cardiology</i> , 2018, 14, 501-508.   | 0.8 | 4         |
| 46 | An improved extraction protocol for therapeutic dabigatran monitoring using HPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1130-1131, 121808.   | 2.3 | 4         |
| 47 | &lt;p&gt;Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects&lt;p&gt;. <i>Pharmacogenomics and Personalized Medicine</i> , 2019, Volume 12, 329-339. | 0.7 | 4         |
| 48 | Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder. <i>Pharmacogenomics Journal</i> , 2021, 21, 435-439.   | 2.0 | 4         |
| 49 | Advanced Age as a Risk Factor of Drug-Induced Diseases. <i>Safety and Risk of Pharmacotherapy</i> , 2021, 9, 15-24.  | 0.2 | 4         |
| 50 | The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2020, 12, 24-31.     | 1.2 | 4         |
| 51 | FREQUENCY OF CYP2C19 AND ABCB1 GENES POLYMORPHISMS, ASSOCIATED WITH THE CHANGE, CAUSED BY CLOPIDOGREL ANTIAGREGANT AMONG THE RUSSIANS AND THE BURYATS. <i>Siberian Medical Review</i> , 2018, , 43-50.   | 0.2 | 4         |
| 52 | Atrial Fibrillation Associated with Anticancer Drugs. <i>Safety and Risk of Pharmacotherapy</i> , 2020, 8, 178-190.  | 0.2 | 4         |
| 53 | Drugâ€“drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Drug Interactions</i> , 2020, 35, .   | 0.3 | 4         |
| 54 | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2013, 9, 404-408.  | 0.8 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH CARDIOEMBOLIC STROKE IN ACUTE PHASE. Rational Pharmacotherapy in Cardiology, 2016, 12, 253-259.   | 0.8 | 3         |
| 56 | FROM PERSONALIZED TO PRECISION MEDICINE. Rational Pharmacotherapy in Cardiology, 2017, 13, 69-79.   | 0.8 | 3         |
| 57 | The Development of New Factor Xa Inhibitors Based on Amide Synthesis. Current Drug Discovery Technologies, 2018, 15, 335-350.   | 1.2 | 3         |
| 58 | Genotyping and phenotyping CYP3A4/CYP3A5: no association with antiplatelet effect of clopidogrel. Molecular Biology Reports, 2019, 46, 4195-4199.   | 2.3 | 3         |
| 59 | Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. Pharmacogenomics, 2020, 21, 111-123.   | 1.3 | 3         |
| 60 | Clinically relevant pharmacogenetic markers in Tatars and Balkars. Molecular Biology Reports, 2020, 47, 3377-3387.  | 2.3 | 3         |
| 61 | Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin. Safety and Risk of Pharmacotherapy, 2021, 9, 25-33.            | 0.2 | 3         |
| 62 | Evaluation of the Influence of <i>CYP2C9*2, CYP2C9*3</i> Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery. Rational Pharmacotherapy in Cardiology, 2021, 17, 570-575. | 0.8 | 3         |
| 63 | Is it possible to use rimilovir to prevent infection and treat COVID-19?. Kachestvennaya Klinicheskaya Praktika, 2020, , 15-17.   | 0.5 | 3         |
| 64 | Falls in the stationary for patients with cardiovascular diseases of the senior age and polypharmacy. Nervno-Myshechnye Bolezni, 2018, 8, 19-27.  | 0.4 | 3         |
| 65 | Falls in elderly patients with comorbidity, which were prescribed combined application of psychotropic and cardiovascular medicines. Nervno-Myshechnye Bolezni, 2019, 9, 67-74.   | 0.4 | 3         |
| 66 | Current and future use of favipiravir in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 106-114.  | 0.5 | 3         |
| 67 | Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice. Kachestvennaya Klinicheskaya Praktika, 2020, , 115-119.   | 0.5 | 3         |
| 68 | Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 18-22.   | 0.5 | 3         |
| 69 | Rationality of routine clinical use of olokizumab in COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 68-70.  | 0.5 | 3         |
| 70 | MicroRNAs as Novel Biomarkers for P2Y12 Inhibitors Resistance Prediction. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1575-1582.   | 0.7 | 3         |
| 71 | Genetic Risk Factors for Adverse Drug Reactions. Safety and Risk of Pharmacotherapy, 2022, 10, 48-64.   | 0.2 | 3         |
| 72 | Pheno- and genotyping the prescription of drugs metabolized by CYP2D6. Bulletin of Experimental Biology and Medicine, 2002, 134, 159-160.   | 0.8 | 2         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Importance of the Pharmacokinetics of Valproic Acid in an Individualized Approach to the Treatment of Epileptic Women of Fertile Age. <i>Neuroscience and Behavioral Physiology</i> , 2012, 42, 963-968.  | 0.4 | 2         |
| 74 | Development of the ontology of patient management technological records for modeling of clinical workflows in a general hospital. <i>Scientific and Technical Information Processing</i> , 2015, 42, 455-462.   | 0.6 | 2         |
| 75 | The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, 9, 59.  | 0.7 | 2         |
| 76 | Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients. <i>Drug Metabolism and Personalized Therapy</i> , 2017, 32, 109-114.   | 0.6 | 2         |
| 77 | FALLING OF SENILE AGE PATIENT AS AN ADVERSE EVENT ASSOCIATED WITH THE USE OF MEDICINES: CASE REPORT. <i>Rational Pharmacotherapy in Cardiology</i> , 2017, 13, 203-206.   | 0.8 | 2         |
| 78 | Aspects of practical application of "STOPP/START" criteria in elderly patients with atrial fibrillation and chronic kidney disease in therapeutic department of multi-speciality hospital. <i>Medical Alphabet</i> , 2021, , 57-65.   | 0.2 | 2         |
| 79 | Efficiency and safety of pharmacotherapy for postoperative pain in cardiac surgery. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021, 20, 2683.   | 1.4 | 2         |
| 80 | Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, .   | 0.9 | 2         |
| 81 | The effect of CYP2D6 and CYP2C9 gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy. <i>Drug Metabolism and Personalized Therapy</i> , 2021, . | 0.6 | 2         |
| 82 | Methotrexate Safety in Psoriasis: An Overview. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 254-267.   | 0.6 | 2         |
| 83 | GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA. <i>Russian Journal of Cardiology</i> , 2015, , 92.   | 1.4 | 2         |
| 84 | Drug-induced atrial fibrillation associated with admission of cardiovascular medications. <i>Siberian Medical Review</i> , 2020, , 5-13.  | 0.2 | 2         |
| 85 | Risk of postoperative venous thromboembolic complication development in elderly patients. <i>Bulletin of Siberian Medicine</i> , 2018, 17, 85-93.   | 0.3 | 2         |
| 86 | Current methods of optimization of pharmacotherapy in elderly patients in multidisciplinary hospital.. <i>Klinicheskaia Meditsina</i> , 2018, 95, 1042-1049.  | 0.1 | 2         |
| 87 | Possibility to use barycytinib in patients with COVID-19, including for treatment of "cytokine storm". <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 11-14.  | 0.5 | 2         |
| 88 | Current and future use of colchicine in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020, , 71-74.   | 0.5 | 2         |
| 89 | Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. <i>Drug Metabolism and Personalized Therapy</i> , 2020, 35, .  | 0.6 | 2         |
| 90 | CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 200-208.   | 0.8 | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug Metabolism and Personalized Therapy, 2022, 37, 41-46.  | 0.6 | 2         |
| 92  | Multifunctional clinical decision support system based on clinical practice guidelines. , 2015, , .  |     | 1         |
| 93  | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case. Rational Pharmacotherapy in Cardiology, 2018, 14, 699-702.                          | 0.8 | 1         |
| 94  | CYP3A subfamily activity affects the equilibrium concentration of Phenazepam<sup>Â®</sup> in patients with anxiety disorders and comorbid alcohol use disorder. Pharmacogenomics, 2020, 21, 449-457.   | 1.3 | 1         |
| 95  | Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. British Journal of Clinical Pharmacology, 2021, 87, 725-729.  | 2.4 | 1         |
| 96  | Olanzapine-Associated Rhabdomyolysis: A Case Report. Cureus, 2021, 13, e12568.   | 0.5 | 1         |
| 97  | Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results. Meditsinskiy Sovet, 2021, , 41-46.                     | 0.5 | 1         |
| 98  | The Continuity of Chronic Medications in Multimorbid Patients during Perioperative Period: Retrospective Analysis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 210-220.  | 0.6 | 1         |
| 99  | Some groups of drugs which use is associated with development of drug-induced atrial fibrillation. Medical Alphabet, 2021, 1, 20-28.   | 0.2 | 1         |
| 100 | Female Gender as a Risk Factor for the Development of Drug-Induced Diseases. Safety and Risk of Pharmacotherapy, 2021, 9, 85-94.   | 0.2 | 1         |
| 101 | Analysis of the composition of hospitalized patients with the new coronavirus infection COVID-19. Zdravookhranenie Rossiiskoi Federatsii / Ministerstvo Zdravookhraneniia RSFSR, 2021, 65, 183-190.  | 0.4 | 1         |
| 102 | CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. Drug Metabolism and Personalized Therapy, 2021, , .   | 0.6 | 1         |
| 103 | Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 299-306.                                      | 0.6 | 1         |
| 104 | CYTOKINE GENE POLYMORPHISMS AS PREDICTORS OF CHRONIC PAIN SYNDROME IN ONCOLOGY. Siberian Journal of Oncology, 2017, 16, 87-94.   | 0.3 | 1         |
| 105 | Comparative analysis of activity of cytochrome isoenzyme P450 CYP2C9 in elderly and senile patients and with that in healthy volunteers of the first period of middle age. Medical News of North Caucasus, 2017, 12, .                         | 0.1 | 1         |
| 106 | Pharmacogenetic evaluation of adverse eventsâ€™ risk in patients with alcohol withdrawal syndrome taking bromdihydrochlorphenylbenzodiazepine: The role of CYP2C19 gene polymorphisms. World Journal of Personalized Medicine, 2017, 1, 18-26. | 0.3 | 1         |
| 107 | Pharmacodynamic gene polymorphism and adverse drug reactionsthen applying antipsychotic drugs. World Journal of Personalized Medicine, 2017, 1, 5-12.  | 0.3 | 1         |
| 108 | Stages of development and implementation of personalized medicine technologies in clinical practice. World Journal of Personalized Medicine, 2017, 1, 1-4.   | 0.3 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | IMPACT OF CYP3A5, CYP2C9, CYP2C19, AND CYP2D6 POLYMORPHISMS ON PHENAZEPAM SAFETY IN PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2018, 73, 206-214.                                   | 0.6 | 1         |
| 110 | Influence of CYP3A Activity on the Efficacy and Safety of Fluvoxamine in Patients Depressive Disorders and Comorbid Alcohol Use Disorder. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2018, 73, 411-419.                        | 0.6 | 1         |
| 111 | Evaluation of the rivaroxaban-influenced effect of ABCB1 and CYP3A5 gene polymorphisms on prothrombin time in patients after total hip or knee replacement surgery. Bulletin of Russian State Medical University, 2018, , 105-109.  | 0.2 | 1         |
| 112 | Tapering (deprescribing) of benzodiazepine tranquilizers. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 89-95.  | 1.2 | 1         |
| 113 | Prevalence of polymorphisms in N-acetyltransferase 2 gene among patients of Yakut ethnicity newly diagnosed with pulmonary tuberculosis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2020, 75, 154-161.                         | 0.6 | 1         |
| 114 | Pain pharmacogenetics. Drug Metabolism and Personalized Therapy, 2020, 35, .  | 0.6 | 1         |
| 115 | Implementation of clinical decision support system for anticoagulant prescribing for patients with deep vein thrombosis. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2020, 75, 69-76.   | 0.6 | 1         |
| 116 | Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab. Kachestvennaya Klinicheskaya Praktika, 2020, , 23-27.                            | 0.5 | 1         |
| 117 | What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?. Kachestvennaya Klinicheskaya Praktika, 2020, , 47-49.                            | 0.5 | 1         |
| 118 | Current and future use of umifenovir in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 75-80.   | 0.5 | 1         |
| 119 | Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention. Kachestvennaya Klinicheskaya Praktika, 2020, , 90-91.   | 0.5 | 1         |
| 120 | Current and future use of dipyridamole in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 92-95.   | 0.5 | 1         |
| 121 | Drug-induced hyponatremia. Siberian Medical Review, 2021, 6, 22-34.   | 0.2 | 1         |
| 122 | Efficiency of treatment of laryngopharyngeal reflux with proton pump inhibitors depending on the <i>CYP2C19</i> polymorphism. Meditsinskiy Sovet, 2022, , 35-43.  | 0.5 | 1         |
| 123 | Pharmacogenetics of antiviral agents for the treatment of COVID-19. Farmakogenetika I Farmakogenomika, 2022, , 38-41.   | 0.0 | 1         |
| 124 | Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2. Sovremennaya Revmatologiya, 2022, 16, 60-67. | 0.5 | 1         |
| 125 | CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. Drug Metabolism and Personalized Therapy, 2022, 37, 47-53.                                     | 0.6 | 1         |
| 126 | SPEECH AND MENTAL DEVELOPMENT IN CHILDREN WITH CEREBRAL PALSY. ZabajkalĖ <sup>1</sup> skij Medicinskij Vestnik, 2020, , 18-24.  | 0.2 | 1         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Drug-induced hypertension. Medical Alphabet, 2022, , 8-13.  | 0.2 | 1         |
| 128 | Drug-induced pulmonary artery hypertension. Kachestvennaya Klinicheskaya Praktika, 2022, , 53-63.   | 0.5 | 1         |
| 129 | Pages from the history of therapeutic schools of the Central Institute for Improvement of Doctors â€“ Russian Medical Academy of Continuous Professional Education. Terapevticheskii Arkhiv, 2022, 94, 596-599.   | 0.8 | 1         |
| 130 | CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE. Rational Pharmacotherapy in Cardiology, 2017, 13, 771-775.   | 0.8 | 0         |
| 131 | PHARMACOGENETIC STUDIES IN CARDIOLOGY: THE PROBLEM OF "DEPTH" OF THE ISSUE STUDY AND THE CORRECTNESS OF USING "GENETIC" TERMS. Rational Pharmacotherapy in Cardiology, 2018, 14, 137-139.   | 0.8 | 0         |
| 132 | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME. Rational Pharmacotherapy in Cardiology, 2018, 14, 47-52.  | 0.8 | 0         |
| 133 | Comparison of Quantitative Analytical Techniques for Dabigatran in Blood Plasma of Humans with Knee Replacements. Pharmaceutical Chemistry Journal, 2019, 53, 771-774.  | 0.8 | 0         |
| 134 | Vitamin D and chronic spontaneous urticaria: searching for algorithms of personalized therapy. Russian Journal of Allergy, 2020, 17, 95-101.  | 0.2 | 0         |
| 135 | Polymorphism 3435c> t of the ABCB1 gene (rs1045642) does not affect the mirtazapine efficiency and safety profile in patients with depressive disorders comorbid with alcohol use disorder. Bulletin of Siberian Medicine, 2021, 19, 73-79.                         | 0.3 | 0         |
| 136 | Comparative analysis of N-acetyltransferase 2 genotyping results among patients with newly diagnosed pulmonary tuberculosis residing in the Sakha Republic (Yakutia). Bulletin of Siberian Medicine, 2021, 19, 102-109.   | 0.3 | 0         |
| 137 | MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring. Drug Metabolism and Personalized Therapy, 2021, .  | 0.6 | 0         |
| 138 | Analysis of associations between pharmacodynamic genetic factors and antipsychoticsâ€™ effectiveness and safety in adolescents with acute psychotic episodes taking antipsychotics during a 28-day follow-up. Kachestvennaya Klinicheskaya Praktika, 2021, , 78-88. | 0.5 | 0         |
| 139 | Alcohol as a risk factor for drug-induced diseases. Kachestvennaya Klinicheskaya Praktika, 2021, , 52-66.   | 0.5 | 0         |
| 140 | Drugs associated with drug-induced interstitial lung diseases. Kachestvennaya Klinicheskaya Praktika, 2021, , 39-51.  | 0.5 | 0         |
| 141 | Changes in anticoagulant prescription in a general hospital in 2008-2018. Rational Pharmacotherapy in Cardiology, 2021, 17, 544-551.  | 0.8 | 0         |
| 142 | Pharmacogenetic approach to methotrexate-related toxicity prediction in psoriasis. Russian Journal of Skin and Venereal Diseases, 2021, 24, 119-132.  | 0.2 | 0         |
| 143 | CYTOCHROME P450 (CYP2C9) ACTIVENESS, EVALUATED VIA LOSARTAN TEST, AS PREDICTION MARKER FOR THE WARFARIN TREATMENT DOSAGE CHOICE IN PATIENTS WITH DELAYED OUTCOMES AFTER HEART VALVES REPLACEMENT. Russian Journal of Cardiology, 2015, , 70.                        | 1.4 | 0         |
| 144 | Personalisation of antiplatelet therapy and secondary prevention of ischemic stroke.. Klinicheskaia Meditsina, 2018, 96, 677-687.   | 0.1 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | Approaches to predicting the efficacy and safety of amlodipine in patients with arterial hypertension of I-II degree based on pharmacogenetic studies. Medical News of North Caucasus, 2019, 14, .  | 0.1 | 0         |
| 146 | Association of CYP3A5 (6986A>G) gene polymorphism with the effectiveness of anti-inflammatory therapy in children with bronchial asthma. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2019, 64, 73-77.   | 0.3 | 0         |
| 147 | The Effect of Cyp2d6 Gene Polymorphism on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders Comorbid with Alcohol. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2019, 74, 185-191.  | 0.6 | 0         |
| 148 | MicroRNA and vascular pathology of the eye. Bulletin of Russian State Medical University, 2020, , 5-9.  | 0.2 | 0         |
| 149 | Problems of integrating medical science, image and practical health care: focus on personalized medicine. Farmakogenetika I Farmakogenomika, 2020, , 3-10.  | 0.0 | 0         |
| 150 | Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects. Meditsinskiy Sovet, 2020, , 65-73.   | 0.5 | 0         |
| 151 | The impact of polypharmacy, compliance with the STOP/START criteria on the risk of falls in elderly patients in a hospital. Åkutskiy Medicinskiy Åurnal, 2020, , 31-33.   | 0.1 | 0         |
| 152 | The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome. Bulletin of Siberian Medicine, 2020, 18, 119-126.  | 0.3 | 0         |
| 153 | The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy. Sklifosovsky Journal Emergency Medical Care, 2020, 9, 391-399. | 0.6 | 0         |
| 154 | Rationale for use mefloquine for COVID-19 treatment. Kachestvennaya Klinicheskaya Praktika, 2020, , 103-105.  | 0.5 | 0         |
| 155 | Current and future use of angiotensin II receptor blockers in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 28-31.   | 0.5 | 0         |
| 156 | Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?. Kachestvennaya Klinicheskaya Praktika, 2020, , 32-34.   | 0.5 | 0         |
| 157 | Possibilities for the use of tofacitinib in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 35-38.   | 0.5 | 0         |
| 158 | Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for Åcytokine stormÅ therapy. Kachestvennaya Klinicheskaya Praktika, 2020, , 4-7.   | 0.5 | 0         |
| 159 | Could canakinumab be used for COVID-19?. Kachestvennaya Klinicheskaya Praktika, 2020, , 50-52.  | 0.5 | 0         |
| 160 | Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 53-59.  | 0.5 | 0         |
| 161 | Possibilities for the use of anakinra in COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 60-63.  | 0.5 | 0         |
| 162 | Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge. Kachestvennaya Klinicheskaya Praktika, 2020, , 64-67.   | 0.5 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Possibility for the use of bromhexine to prevent infection with SARS-CoV-2. Kachestvennaya Klinicheskaya Praktika, 2020, , 8-10.   | 0.5 | 0         |
| 164 | Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel. Kachestvennaya Klinicheskaya Praktika, 2020, , 81-86.   | 0.5 | 0         |
| 165 | Current and future use of vitamin D <sup>3</sup> in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 87-89.  | 0.5 | 0         |
| 166 | Dexamethasone use in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 96-98.   | 0.5 | 0         |
| 167 | Current and future use of remdesivir in patients with COVID-19. Kachestvennaya Klinicheskaya Praktika, 2020, , 99-102.   | 0.5 | 0         |
| 168 | Anaphylaxis and vitamin D: associations and perspectives. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2020, 65, 31-36.   | 0.3 | 0         |
| 169 | Influence of the Acetylation Type on the Incidence of Isoniazid-Induced Hepatotoxicity in Patients with Newly Diagnosed Pulmonary Tuberculosis. Antibiotiki I Khimioterapiya, 2020, 65, 31-36.   | 0.6 | 0         |
| 170 | Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology Bulletin, 2021, 51, 69-80.   | 0.0 | 0         |
| 171 | Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology Bulletin, 2021, 51, 31-42.   | 0.0 | 0         |
| 172 | Determination of the pharmacokinetic parameters of isoniazid using high performance liquid chromatography in patients with pulmonary tuberculosis. Ākutschij Medicinskij Āžurnal, 2021, , 52-55.   | 0.1 | 0         |
| 173 | Importance of using a pharmacogenetic approach to predict individual pharmacokinetics and safety profile of apixaban. Farmakogenetika I Farmakogenomika, 2022, , 4-8.  | 0.0 | 0         |
| 174 | Influence of the NAT2 gene polymorphic markers on the effectiveness and safety of treatment in patients with newly diagnosed pulmonary tuberculosis based on peripheral red blood cell dynamics. Antibiotiki I Khimioterapiya, 2022, 66, 30-38.  | 0.6 | 0         |
| 175 | Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis. Kachestvennaya Klinicheskaya Praktika, 2020, , 39-46.   | 0.5 | 0         |
| 176 | CYP2C8, PTGS-1, 2 gene polymorphisms prevalence associated with sensitivity to non-steroidal anti-inflammatory drugs among North Caucasus ethnic groups. Terapevticheskii Arkhiv, 2021, 93, 1334-1339.   | 0.8 | 0         |
| 177 | Drug-Induced Atrial Fibrillation / Atrial Flutter. Rational Pharmacotherapy in Cardiology, 2022, 17, 1-18.   | 0.8 | 0         |
| 178 | Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. Psychopharmacology Bulletin, 2021, 51, 87-104.   | 0.0 | 0         |
| 179 | Consensus expert opinion on key items in planning and designing clinical trials in geriatric patients. Russian Journal of Geriatric Medicine, 2022, , 398-402.   | 0.6 | 0         |
| 180 | The effect of <i>CYP2D6</i> and <i>CYP2C9</i> gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy. Drug Metabolism and Personalized Therapy, 2022, 37, 27-34. | 0.6 | 0         |

